Engineering the Microbiome: a Novel Approach to Immunotherapy for Allergic and Immune Diseases

Current Allergy and Asthma Reports

Volumn 15, Issue 7, 2015, Pages

  Shen, Nan ^a   Clemente, Jose C ^a  

^a MOUNT SINAI SCHOOL OF MEDICINE   (United States)

Author keywords

Allergy; Antibiotics; Dietary intervention; Fecal transplant; IBD; Microbiome

Indexed keywords

ANTIBIOTIC AGENT;

ALLERGIC DISEASE; ANTIBIOTIC THERAPY; BIOENGINEERING; BIOLOGICAL THERAPY; DIET THERAPY; FECAL MICROBIOTA TRANSPLANTATION; FOOD ALLERGY; HOST RESISTANCE; HUMAN; IMMUNOMODULATION; IMMUNOTHERAPY; INFLAMMATORY BOWEL DISEASE; INTESTINE FLORA; NONHUMAN; REVIEW; WESTERN DIET; ANIMAL; FOOD; GASTROINTESTINAL TRACT; HYPERSENSITIVITY; IMMUNOLOGY; INFLAMMATION; MICROBIOLOGY; MICROFLORA;

ANIMALS; FOOD; GASTROINTESTINAL TRACT; HUMANS; HYPERSENSITIVITY; IMMUNOTHERAPY; INFLAMMATION; MICROBIOTA;

EID: 84937432753     PISSN: 15297322     EISSN: 15346315     Source Type: Journal    
DOI: 10.1007/s11882-015-0538-9     Document Type: Review

References (137)

1. Sicherer SH, Munoz-Furlong A, Godbold JH, Sampson HA. US prevalence of self-reported peanut, tree nut, and sesame allergy: 11-year follow-up. J Allergy Clin Immunol. 2010;125:1322–6. doi:10.1016/j.jaci.2010.03.029.
2. Molodecky NA et al. Increasing incidence and prevalence of the inflammatory bowel diseases with time, based on systematic review. Gastroenterology. 2012;142:46–54. doi:10.1053/j.gastro.2011.10.001. e42; quiz e30.
3. Grundy J, Matthews S, Bateman B, Dean T, Arshad SH. Rising prevalence of allergy to peanut in children: data from 2 sequential cohorts. J Allergy Clin Immunol. 2002;110:784–9.
4. Mullins RJ, Dear KB, Tang ML. Characteristics of childhood peanut allergy in the Australian Capital Territory, 1995 to 2007. J Allergy Clin Immunol. 2009;123:689–93. doi:10.1016/j.jaci.2008.12.1116.
5. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006;355:2226–35. doi:10.1056/NEJMra054308.
6. Dominguez-Bello MG et al. Delivery mode shapes the acquisition and structure of the initial microbiota across multiple body habitats in newborns. Proc Natl Acad Sci U S A. 2010;107:11971–5. doi:10.1073/pnas.1002601107.
7. Cox LM et al. Altering the intestinal microbiota during a critical developmental window has lasting metabolic consequences. Cell. 2014;158:705–21. doi:10.1016/j.cell.2014.05.052.
8. Thorburn AN, Macia L, Mackay CR. Diet, metabolites, and “western-lifestyle” inflammatory diseases. Immunity. 2014;40:833–42. doi:10.1016/j.immuni.2014.05.014.
9. Garrett WS et al. Communicable ulcerative colitis induced by T-bet deficiency in the innate immune system. Cell. 2007;131:33–45. doi:10.1016/j.cell.2007.08.017.
10. Noval Rivas M et al. A microbiota signature associated with experimental food allergy promotes allergic sensitization and anaphylaxis. J Allergy Clin Immunol. 2013;131:201–12. doi:10.1016/j.jaci.2012.10.026. This article demonstrates the existence of transmissible allergy-prone microbiota, linking gut microbiota to food allergy directly for the first time.
11. Trompette A et al. Gut microbiota metabolism of dietary fiber influences allergic airway disease and hematopoiesis. Nat Med. 2014;20:159–66. doi:10.1038/nm.3444. This study shows evidence at the cellular level of an association between gut microbiota and bone marrow hemapoiesis, suggesting the microbiota can be a target for immune disorders at some sites other than in the GI tract.
12. Rajilic-Stojanovic M, Heilig HG, Tims S, Zoetendal EG, de Vos WM. Long-term monitoring of the human intestinal microbiota composition. Environ Microbiol. 2012. doi:10.1111/1462-2920.12023.
13. Faith JJ et al. The long-term stability of the human gut microbiota. Science. 2013;341:1237439. doi:10.1126/science.1237439.
14. Koropatkin NM, Cameron EA, Martens EC. How glycan metabolism shapes the human gut microbiota. Nat Rev Microbiol. 2012;10:323–35. doi:10.1038/nrmicro2746.
15. Bird JJ et al. Helper T cell differentiation is controlled by the cell cycle. Immunity. 1998;9:229–37.
16. Peng L, He Z, Chen W, Holzman IR, Lin J. Effects of butyrate on intestinal barrier function in a Caco-2 cell monolayer model of intestinal barrier. Pediatr Res. 2007;61:37–41. doi:10.1203/01.pdr.0000250014.92242.f3.
17. Yatsunenko T et al. Human gut microbiome viewed across age and geography. Nature. 2012;486:222–7. doi:10.1038/nature11053.
18. Martin R et al. Early life: gut microbiota and immune development in infancy. Benefic Microbes. 2010;1:367–82. doi:10.3920/BM2010.0027.
19. Ouwehand AC. Antiallergic effects of probiotics. J Nutr. 2007;137:794S–7.
20. Debock I, Flamand V. Unbalanced neonatal CD4(+) T-cell immunity. Front Immunol. 2014;5:393. doi:10.3389/fimmu.2014.00393.
21. von der Weid T, Bulliard C, Schiffrin EJ. Induction by a lactic acid bacterium of a population of CD4(+) T cells with low proliferative capacity that produce transforming growth factor beta and interleukin-10. Clin Diagn Lab Immunol. 2001;8:695–701. doi:10.1128/CDLI.8.4.695-701.2001.
22. Kirjavainen PV, Gibson GR. Healthy gut microflora and allergy: factors influencing development of the microbiota. Ann Med. 1999;31:288–92.
23. Artis D. Epithelial-cell recognition of commensal bacteria and maintenance of immune homeostasis in the gut. Nat Rev Immunol. 2008;8:411–20. doi:10.1038/nri2316.
24. Kim HG et al. Lactobacillus plantarum lipoteichoic acid down-regulated Shigella flexneri peptidoglycan-induced inflammation. Mol Immunol. 2011;48:382–91. doi:10.1016/j.molimm.2010.07.011.
25. Fukuda S, Toh H, Taylor TD, Ohno H, Hattori M. Acetate-producing bifidobacteria protect the host from enteropathogenic infection via carbohydrate transporters. Gut Microbes. 2012;3:449–54. doi:10.4161/gmic.21214.
26. Esplugues E et al. Control of TH17 cells occurs in the small intestine. Nature. 2011;475:514–8. doi:10.1038/nature10228.
27. Ivanov II et al. Induction of intestinal Th17 cells by segmented filamentous bacteria. Cell. 2009;139:485–98. doi:10.1016/j.cell.2009.09.033.
28. Mazmanian SK, Liu CH, Tzianabos AO, Kasper DL. An immunomodulatory molecule of symbiotic bacteria directs maturation of the host immune system. Cell. 2005;122:107–18. doi:10.1016/j.cell.2005.05.007.
29. Round JL et al. The Toll-like receptor 2 pathway establishes colonization by a commensal of the human microbiota. Science. 2011;332:974–7. doi:10.1126/science.1206095.
30. Atarashi K et al. Induction of colonic regulatory T cells by indigenous Clostridium species. Science. 2011;331:337–41. doi:10.1126/science.1198469.
31. Sokol H et al. Faecalibacterium prausnitzii is an anti-inflammatory commensal bacterium identified by gut microbiota analysis of Crohn disease patients. Proc Natl Acad Sci U S A. 2008;105:16731–6. doi:10.1073/pnas.0804812105.
32. Wang J. Food allergy: recent advances in pathophysiology and treatment. Allergy Asthma Immunol Res. 2009;1:19–29. doi:10.4168/aair.2009.1.1.19.
33. Kunisawa J, Kiyono H. Aberrant interaction of the gut immune system with environmental factors in the development of food allergies. Curr Allergy Asthma Rep. 2010;10:215–21. doi:10.1007/s11882-010-0097-z.
34. Berin MC, Mayer L. Can we produce true tolerance in patients with food allergy? J Allergy Clin Immunol. 2013;131:14–22. doi:10.1016/j.jaci.2012.10.058.
35. Noverr MC, Huffnagle GB. The ‘microflora hypothesis’ of allergic diseases. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2005;35:1511–20. doi:10.1111/j.1365-2222.2005.02379.x.
36. Penders J, Stobberingh EE, van den Brandt PA, Thijs C. The role of the intestinal microbiota in the development of atopic disorders. Allergy. 2007;62:1223–36. doi:10.1111/j.1398-9995.2007.01462.x.
37. Viljanen M et al. Probiotics in the treatment of atopic eczema/dermatitis syndrome in infants: a double-blind placebo-controlled trial. Allergy. 2005;60:494–500. doi:10.1111/j.1398-9995.2004.00514.x.
38. Pohjavuori E et al. Lactobacillus GG effect in increasing IFN-gamma production in infants with cow’s milk allergy. J Allergy Clin Immunol. 2004;114:131–6. doi:10.1016/j.jaci.2004.03.036.
39. Sanchez E, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Intestinal Bacteroides species associated with coeliac disease. J Clin Pathol. 2010;63:1105–11. doi:10.1136/jcp.2010.076950.
40. Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Specific duodenal and faecal bacterial groups associated with paediatric coeliac disease. J Clin Pathol. 2009;62:264–9. doi:10.1136/jcp.2008.061366.
41. Collado MC, Donat E, Ribes-Koninckx C, Calabuig M, Sanz Y. Imbalances in faecal and duodenal Bifidobacterium species composition in active and non-active coeliac disease. BMC Microbiol. 2008;8:232. doi:10.1186/1471-2180-8-232.
42. Sartor RB. Mechanisms of disease: pathogenesis of Crohn’s disease and ulcerative colitis. Nat Clin Pract Gastroenterol Hepatol. 2006;3:390–407. doi:10.1038/ncpgasthep0528.
43. Spehlmann ME et al. Epidemiology of inflammatory bowel disease in a German twin cohort: results of a nationwide study. Inflamm Bowel Dis. 2008;14:968–76. doi:10.1002/ibd.20380.
44. Orholm M, Binder V, Sorensen TI, Rasmussen LP, Kyvik KO. Concordance of inflammatory bowel disease among Danish twins. Results of a nationwide study. Scand J Gastroenterol. 2000;35:1075–81.
45. Halfvarson J, Bodin L, Tysk C, Lindberg E, Jarnerot G. Inflammatory bowel disease in a Swedish twin cohort: a long-term follow-up of concordance and clinical characteristics. Gastroenterology. 2003;124:1767–73.
46. Prescott NJ et al. A nonsynonymous SNP in ATG16L1 predisposes to ileal Crohn’s disease and is independent of CARD15 and IBD5. Gastroenterology. 2007;132:1665–71. doi:10.1053/j.gastro.2007.03.034.
47. Sartor RB. Current concepts of the etiology and pathogenesis of ulcerative colitis and Crohn’s disease. Gastroenterol Clin N Am. 1995;24:475–507.
48. Sellon RK et al. Resident enteric bacteria are necessary for development of spontaneous colitis and immune system activation in interleukin-10-deficient mice. Infect Immun. 1998;66:5224–31.
49. Kullberg MC et al. Helicobacter hepaticus triggers colitis in specific-pathogen-free interleukin-10 (IL-10)-deficient mice through an IL-12- and gamma interferon-dependent mechanism. Infect Immun. 1998;66:5157–66.
50. Devkota S et al. Dietary-fat-induced taurocholic acid promotes pathobiont expansion and colitis in Il10-/- mice. Nature. 2012;487:104–8. doi:10.1038/nature11225.
51. Balish E, Warner T. Enterococcus faecalis induces inflammatory bowel disease in interleukin-10 knockout mice. Am J Pathol. 2002;160:2253–7. doi:10.1016/S0002-9440(10)61172-8.
52. Kim SC et al. Variable phenotypes of enterocolitis in interleukin 10-deficient mice monoassociated with two different commensal bacteria. Gastroenterology. 2005;128:891–906.
53. Machiels K et al. A decrease of the butyrate-producing species Roseburia hominis and Faecalibacterium prausnitzii defines dysbiosis in patients with ulcerative colitis. Gut. 2014;63:1275–83. doi:10.1136/gutjnl-2013-304833.
54. Gevers D et al. The treatment-naive microbiome in new-onset Crohn’s disease. Cell Host Microbe. 2014;15:382–92. doi:10.1016/j.chom.2014.02.005.
55. Tong M et al. A modular organization of the human intestinal mucosal microbiota and its association with inflammatory bowel disease. PLoS One. 2013;8, e80702. doi:10.1371/journal.pone.0080702.
56. Morgan XC et al. Dysfunction of the intestinal microbiome in inflammatory bowel disease and treatment. Genome Biol. 2012;13:R79. doi:10.1186/gb-2012-13-9-r79.
57. Turroni F et al. Diversity of bifidobacteria within the infant gut microbiota. PLoS One. 2012;7, e36957. doi:10.1371/journal.pone.0036957.
58. Le Pendu J. Histo-blood group antigen and human milk oligosaccharides: genetic polymorphism and risk of infectious diseases. Adv Exp Med Biol. 2004;554:135–43.
59. Verhasselt V. Neonatal tolerance under breastfeeding influence. Curr Opin Immunol. 2010;22:623–30. doi:10.1016/j.coi.2010.08.008.
60. Labeta MO et al. Innate recognition of bacteria in human milk is mediated by a milk-derived highly expressed pattern recognition receptor, soluble CD14. J Exp Med. 2000;191:1807–12.
61. LeBouder E et al. Soluble forms of Toll-like receptor (TLR)2 capable of modulating TLR2 signaling are present in human plasma and breast milk. J Immunol. 2003;171:6680–9.
62. Martin R et al. Cultivation-independent assessment of the bacterial diversity of breast milk among healthy women. Res Microbiol. 2007;158:31–7. doi:10.1016/j.resmic.2006.11.004.
63. Adlerberth I, Wold AE. Establishment of the gut microbiota in Western infants. Acta Paediatr. 2009;98:229–38. doi:10.1111/j.1651-2227.2008.01060.x.
64. Jalanka-Tuovinen J et al. Intestinal microbiota in healthy adults: temporal analysis reveals individual and common core and relation to intestinal symptoms. PLoS One. 2011;6, e23035. doi:10.1371/journal.pone.0023035.
65. Hehemann JH et al. Transfer of carbohydrate-active enzymes from marine bacteria to Japanese gut microbiota. Nature. 2010;464:908–12. doi:10.1038/nature08937.
66. Wu GD et al. Linking long-term dietary patterns with gut microbial enterotypes. Science. 2011;334:105–8. doi:10.1126/science.1208344.
67. Begley M, Gahan CG, Hill C. The interaction between bacteria and bile. FEMS Microbiol Rev. 2005;29:625–51. doi:10.1016/j.femsre.2004.09.003.
68. Jantchou P, Morois S, Clavel-Chapelon F, Boutron-Ruault MC, Carbonnel F. Animal protein intake and risk of inflammatory bowel disease: the E3N prospective study. Am J Gastroenterol. 2010;105:2195–201. doi:10.1038/ajg.2010.192.
69. Walker AW et al. Dominant and diet-responsive groups of bacteria within the human colonic microbiota. ISME J. 2011;5:220–30. doi:10.1038/ismej.2010.118.
70. Fallingborg J. Intraluminal pH of the human gastrointestinal tract. Dan Med Bull. 1999;46:183–96.
71. Duncan SH, Louis P, Thomson JM, Flint HJ. The role of pH in determining the species composition of the human colonic microbiota. Environ Microbiol. 2009;11:2112–22. doi:10.1111/j.1462-2920.2009.01931.x.
72. Zimmer J et al. A vegan or vegetarian diet substantially alters the human colonic faecal microbiota. Eur J Clin Nutr. 2012;66:53–60. doi:10.1038/ejcn.2011.141.
73. Watson D et al. Selective carbohydrate utilization by lactobacilli and bifidobacteria. J Appl Microbiol. 2013;114:1132–46. doi:10.1111/jam.12105.
74. Furusawa Y et al. Commensal microbe-derived butyrate induces the differentiation of colonic regulatory T cells. Nature. 2013;504:446–50. doi:10.1038/nature12721.
75. Fukuda S et al. Bifidobacteria can protect from enteropathogenic infection through production of acetate. Nature. 2011;469:543–7. doi:10.1038/nature09646.
76. Maslowski KM et al. Regulation of inflammatory responses by gut microbiota and chemoattractant receptor GPR43. Nature. 2009;461:1282–6. doi:10.1038/nature08530.
77. Palmer DJ, Makrides M. Diet of lactating women and allergic reactions in their infants. Curr Opin Clin Nutr Metab Care. 2006;9:284–8. doi:10.1097/01.mco.0000222113.46042.50.
78. Verhasselt V et al. Breast milk-mediated transfer of an antigen induces tolerance and protection from allergic asthma. Nat Med. 2008;14:170–5. doi:10.1038/nm1718.
79. Coombes JL et al. A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med. 2007;204:1757–64. doi:10.1084/jem.20070590.
80. Mora JR et al. Generation of gut-homing IgA-secreting B cells by intestinal dendritic cells. Science. 2006;314:1157–60. doi:10.1126/science.1132742.
81. Mucida D et al. Reciprocal TH17 and regulatory T cell differentiation mediated by retinoic acid. Science. 2007;317:256–60. doi:10.1126/science.1145697.
82. Iwata M et al. Retinoic acid imprints gut-homing specificity on T cells. Immunity. 2004;21:527–38. doi:10.1016/j.immuni.2004.08.011.
83. Chang JH, Cha HR, Lee DS, Seo KY, Kweon MN. 1,25-Dihydroxyvitamin D3 inhibits the differentiation and migration of T(H)17 cells to protect against experimental autoimmune encephalomyelitis. PLoS One. 2010;5, e12925. doi:10.1371/journal.pone.0012925.
84. Bruce D, Cantorna MT. Intrinsic requirement for the vitamin D receptor in the development of CD8alphaalpha-expressing T cells. J Immunol. 2011;186:2819–25. doi:10.4049/jimmunol.1003444.
85. Sonnenberg GF, Fouser LA, Artis D. Border patrol: regulation of immunity, inflammation and tissue homeostasis at barrier surfaces by IL-22. Nat Immunol. 2011;12:383–90. doi:10.1038/ni.2025.
86. Li Y et al. Exogenous stimuli maintain intraepithelial lymphocytes via aryl hydrocarbon receptor activation. Cell. 2011;147:629–40. doi:10.1016/j.cell.2011.09.025.
87. Kiss EA et al. Natural aryl hydrocarbon receptor ligands control organogenesis of intestinal lymphoid follicles. Science. 2011;334:1561–5. doi:10.1126/science.1214914.
88. Schulz VJ et al. Activation of the aryl hydrocarbon receptor suppresses sensitization in a mouse peanut allergy model. Toxicol Sci: Off J Soc Toxicol. 2011;123:491–500. doi:10.1093/toxsci/kfr175.
89. Wright JD, Wang CY. Trends in intake of energy and macronutrients in adults from 1999-2000 through 2007–2008. NCHS Data Brief 2010; 1–8.
90. Clemente JC, et al. The microbiome of uncontacted Amerindians. Sci Adv. 2015.
91. Muegge BD et al. Diet drives convergence in gut microbiome functions across mammalian phylogeny and within humans. Science. 2011;332:970–4. doi:10.1126/science.1198719.
92. De Filippo C et al. Impact of diet in shaping gut microbiota revealed by a comparative study in children from Europe and rural Africa. Proc Natl Acad Sci U S A. 2010;107:14691–6. doi:10.1073/pnas.1005963107.
93. de La Serre CB et al. Propensity to high-fat diet-induced obesity in rats is associated with changes in the gut microbiota and gut inflammation. Am J Physiol Gastrointest Liver Physiol. 2010;299:G440–8. doi:10.1152/ajpgi.00098.2010.
94. Jowett SL et al. Influence of dietary factors on the clinical course of ulcerative colitis: a prospective cohort study. Gut. 2004;53:1479–84. doi:10.1136/gut.2003.024828.
95. Cohen SA et al. Clinical and mucosal improvement with specific carbohydrate diet in pediatric Crohn disease. J Pediatr Gastroenterol Nutr. 2014;59:516–21. doi:10.1097/MPG.0000000000000449.
96. Suskind DL, Wahbeh G, Gregory N, Vendettuoli H, Christie D. Nutritional therapy in pediatric Crohn disease: the specific carbohydrate diet. J Pediatr Gastroenterol Nutr. 2014;58:87–91. doi:10.1097/MPG.0000000000000103.
97. Day AS et al. Exclusive enteral feeding as primary therapy for Crohn’s disease in Australian children and adolescents: a feasible and effective approach. J Gastroenterol Hepatol. 2006;21:1609–14. doi:10.1111/j.1440-1746.2006.04294.x.
98. Day AS, Burgess L. Exclusive enteral nutrition and induction of remission of active Crohn’s disease in children. Expert Rev Clin Immunol. 2013;9:375–83. doi:10.1586/eci.13.12. quiz 384.
99. Wall CL, Day AS, Gearry RB. Use of exclusive enteral nutrition in adults with Crohn’s disease: a review. World J Gastroenterol: WJG. 2013;19:7652–60. doi:10.3748/wjg.v19.i43.7652.
100. Heuschkel RB, Menache CC, Megerian JT, Baird AE. Enteral nutrition and corticosteroids in the treatment of acute Crohn’s disease in children. J Pediatr Gastroenterol Nutr. 2000;31:8–15.
101. Tjellstrom B et al. Effect of exclusive enteral nutrition on gut microflora function in children with Crohn’s disease. Scand J Gastroenterol. 2012;47:1454–9. doi:10.3109/00365521.2012.703234.
102. Gerasimidis K et al. Decline in presumptively protective gut bacterial species and metabolites are paradoxically associated with disease improvement in pediatric Crohn’s disease during enteral nutrition. Inflamm Bowel Dis. 2014;20:861–71. doi:10.1097/MIB.0000000000000023.
103. Luna-Pech JA, Torres-Mendoza BM, Garcia-Cobas CY, Navarrete-Navarro S, Elizalde-Lozano AM. Normocaloric diet improves asthma-related quality of life in obese pubertal adolescents. Int Arch Allergy Immunol. 2014;163:252–8. doi:10.1159/000360398.
104. Kim HJ, Yu BP, Chung HY. Molecular exploration of age-related NF-kappaB/IKK downregulation by calorie restriction in rat kidney. Free Radic Biol Med. 2002;32:991–1005.
105. van den Elsen LW et al. CD25+ regulatory T cells transfer n-3 long chain polyunsaturated fatty acids-induced tolerance in mice allergic to cow’s milk protein. Allergy. 2013;68:1562–70. doi:10.1111/all.12300.
106. van den Elsen LW et al. Dietary long chain n-3 polyunsaturated fatty acids prevent allergic sensitization to cow’s milk protein in mice. Clin Exp Allergy: J Br Soc Allergy Clin Immunol. 2013;43:798–810. doi:10.1111/cea.12111.
107. van den Elsen LW et al. DHA-rich tuna oil effectively suppresses allergic symptoms in mice allergic to whey or peanut. J Nutr. 2014;144:1970–6. doi:10.3945/jn.114.198515.
108. Ghosh S et al. Fish oil attenuates omega-6 polyunsaturated fatty acid-induced dysbiosis and infectious colitis but impairs LPS dephosphorylation activity causing sepsis. PLoS One. 2013;8, e55468. doi:10.1371/journal.pone.0055468.
109. Yang N, Song Y, Sampson H, Li X. Bioactivities of berberine, palmatine, and jatrorrhizine isolated from Food Allergy Herbal Formula 2 (FAHF-2). J Allergy Clin Immunol. 2011;127:AB240. doi:10.1016/j.jaci.2010.12.956.
110. Zhang X et al. Structural changes of gut microbiota during berberine-mediated prevention of obesity and insulin resistance in high-fat diet-fed rats. PLoS One. 2012;7, e42529. doi:10.1371/journal.pone.0042529.
111. Wang J. Treatment of food anaphylaxis with traditional Chinese herbal remedies: from mouse model to human clinical trials. Curr Opin Allergy Clin Immunol. 2013;13:386–91. doi:10.1097/ACI.0b013e3283615bc4.
112. David LA et al. Diet rapidly and reproducibly alters the human gut microbiome. Nature. 2014;505:559–63. doi:10.1038/nature12820.
113. Berg D, Clemente JC, Colombel JF. Can inflammatory bowel disease be permanently treated with short-term interventions on the microbiome?. Expert Rev Gastroenterol Hepatol. 2015; 1–15, doi:10.1586/17474124.2015.1013031.
114. Modi SR, Collins JJ, Relman DA. Antibiotics and the gut microbiota. J Clin Invest. 2014;124:4212–8. doi:10.1172/JCI72333.
115. Colombel JF et al. A controlled trial comparing ciprofloxacin with mesalazine for the treatment of active Crohn’s disease. Groupe d’Etudes Therapeutiques des Affections Inflammatoires Digestives (GETAID). Am J Gastroenterol. 1999;94:674–8. doi:10.1111/j.1572-0241.1999.935_q.x.
116. Selby W et al. Two-year combination antibiotic therapy with clarithromycin, rifabutin, and clofazimine for Crohn’s disease. Gastroenterology. 2007;132:2313–9. doi:10.1053/j.gastro.2007.03.031.
117. Prantera C et al. Rifaximin-extended intestinal release induces remission in patients with moderately active Crohn’s disease. Gastroenterology. 2012;142:473–81. doi:10.1053/j.gastro.2011.11.032. e474.
118. Leiper K et al. Clinical trial: randomized study of clarithromycin versus placebo in active Crohn’s disease. Aliment Pharmacol Ther. 2008;27:1233–9. doi:10.1111/j.1365-2036.2008.03661.x.
119. Afdhal NH, Long A, Lennon J, Crowe J, O’Donoghue DP. Controlled trial of antimycobacterial therapy in Crohn’s disease. Clofazimine versus placebo. Dig Dis Sci. 1991;36:449–53.
120. Sutherland L et al. Double blind, placebo controlled trial of metronidazole in Crohn’s disease. Gut. 1991;32:1071–5.
121. Steinhart AH et al. Combined budesonide and antibiotic therapy for active Crohn’s disease: a randomized controlled trial. Gastroenterology. 2002;123:33–40.
122. Ohkusa T et al. Newly developed antibiotic combination therapy for ulcerative colitis: a double-blind placebo-controlled multicenter trial. Am J Gastroenterol. 2010;105:1820–9. doi:10.1038/ajg.2010.84.
123. Turunen UM et al. Long-term treatment of ulcerative colitis with ciprofloxacin: a prospective, double-blind, placebo-controlled study. Gastroenterology. 1998;115:1072–8.
124. Mantzaris GJ et al. A prospective randomized controlled trial of intravenous ciprofloxacin as an adjunct to corticosteroids in acute, severe ulcerative colitis. Scand J Gastroenterol. 2001;36:971–4.
125. Mantzaris GJ et al. A prospective randomized controlled trial of oral ciprofloxacin in acute ulcerative colitis. Am J Gastroenterol. 1997;92:454–6.
126. Dickinson RJ et al. Double blind controlled trial of oral vancomycin as adjunctive treatment in acute exacerbations of idiopathic colitis. Gut. 1985;26:1380–4.
127. Mantzaris GJ, Hatzis A, Kontogiannis P, Triadaphyllou G. Intravenous tobramycin and metronidazole as an adjunct to corticosteroids in acute, severe ulcerative colitis. Am J Gastroenterol. 1994;89:43–6.
128. Gionchetti P et al. Antibiotic combination therapy in patients with chronic, treatment-resistant pouchitis. Aliment Pharmacol Ther. 1999;13:713–8.
129. Dethlefsen L, Huse S, Sogin ML, Relman DA. The pervasive effects of an antibiotic on the human gut microbiota, as revealed by deep 16S rRNA sequencing. PLoS Biol. 2008;6, e280. doi:10.1371/journal.pbio.0060280.
130. Mattila E et al. Fecal transplantation, through colonoscopy, is effective therapy for recurrent Clostridium difficile infection. Gastroenterology. 2012;142:490–6. doi:10.1053/j.gastro.2011.11.037.
131. van Nood E et al. Duodenal infusion of donor feces for recurrent Clostridium difficile. N Engl J Med. 2013;368:407–15. doi:10.1056/NEJMoa1205037.
132. Gough E, Shaikh H, Manges AR. Systematic review of intestinal microbiota transplantation (fecal bacteriotherapy) for recurrent Clostridium difficile infection. Clin Infect Dis: Off Publ Infect Dis Soc Am. 2011;53:994–1002. doi:10.1093/cid/cir632.
133. Youngster I et al. Oral, capsulized, frozen fecal microbiota transplantation for relapsing Clostridium difficile infection. JAMA. 2014;312:1772–8. doi:10.1001/jama.2014.13875. This study shows a novel form of FMT using encapsulated frozen microbiota, opening the way for safer and more efficient ways to modulate microbiome content.
134. Damman CJ, Miller SI, Surawicz CM, Zisman TL. The microbiome and inflammatory bowel disease: is there a therapeutic role for fecal microbiota transplantation? Am J Gastroenterol. 2012;107:1452–9. doi:10.1038/ajg.2012.93.
135. Ianiro G, Bibbo S, Scaldaferri F, Gasbarrini A, Cammarota G. Fecal microbiota transplantation in inflammatory bowel disease: beyond the excitement. Medicine. 2014;93:e97. doi:10.1097/MD.0000000000000097.
136. Shankar V et al. Species and genus level resolution analysis of gut microbiota in Clostridium difficile patients following fecal microbiota transplantation. Microbiome. 2014;2:13. doi:10.1186/2049-2618-2-13.
137. Smits LP, Bouter KE, de Vos WM, Borody TJ, Nieuwdorp M. Therapeutic potential of fecal microbiota transplantation. Gastroenterology. 2013;145:946–53. doi:10.1053/j.gastro.2013.08.058.